Article
EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where gout was high on the agenda.
All News
sheila
Tweet
This retrospective cohort of NPSLE pts
showed clinical assocs with MRI findings: Pts w/ focal symptoms - abn MRI
Pts w/ diffuse symptoms - normal MRI except brain atrophy
Interesting to know how this can aid in future mgt strategies for NPSLE
OP093 @RheumNow #EULAR2026 https://t.co/omvdWk6EZK
Aurelie Najm
Tweet
TOGETHER PsA trial
IXE+TIRZEPATIDE TZP vs. IXE alone RCT
Obese or Overweight PsA IR to <3 bioDMARDs
Primary endpoint ≥10% weight & ACR50 wk 36
31.7% IXE+TZP vs. 0.8% for IXE alone
ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02)
No clear difference by gender/age/BMI/previous DMARDs https://t.co/zBcfpj2MF6
Mrinalini Dey
Tweet
#OP087 explored cancer polygenic risk scores (PRS) in RA. RA was assoc with lower risks of breast and colorectal cancer across all PRS categories, while high prostate cancer PRS may identify RA patients with increased early prostate cancer diagnoses. @RheumNow #EULAR2026 https://t.co/WMqqSFADlW
Aurelie Najm
Tweet
68Ga-RGD PET/CT in PsA reveals large chunk of “silent” synovitis
15 pts 1020 joints
35% affected joints clinically silent
PET signal correlation w/ disease burden:
DAPSA (ρ=0.66)
CRP (ρ=0.69)
Pilot study — not confirmed with US
Needs validation but intriguing signal
#OP068 https://t.co/nhS7PDZN0A
Md Yuzaiful Md Yusof
Tweet
#EULAR2026 OP077 Another promising CAR-T in autoimmunity. In a Phase II study, Rap-Cel autologous CD19 CAR-T (shorter infusion time ~2d & low dose) vs traditional CAR-T showed drug-free improvement in N=6 #IIM & N=6 #SSc patients. Safety similar to other CAR-Ts @RheumNow https://t.co/byNn5X8JGh
Jiha Lee
Tweet
Treating inflammation and obesity in PsA with IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE effective with no new safety signals
OP069 @RheumNow #EULAR2026 https://t.co/rkhYvZWpHn
Antoni Chan MD (Prof)
Tweet
TOGETHER-PsA :ACR50 was already significantly higher with IXE+TZP as early as Week 4 (11.1% vs 3.9%, p=0.029). The metabolic and anti-inflammatory effects of GLP-1/GIP agonism may act synergistically Abstr#069 @RheumNow #EULAR2026 https://t.co/NBQ6CccuCn
TOGETHER PsA trial
IXE+TIRZEPATIDE TZP vs. IXE alone RCT
Obese or Overweight PsA IR to <3 bioDMARDs
Primary endpoint ≥10% weight & ACR50 wk 36
31.7% IXE+TZP vs. 0.8% for IXE alone
ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02)
No clear difference by gender/age/BMI/previous DMARDs https://t.co/lFbeb85b9Y
Mrinalini Dey
Tweet
Cancer risk with JAK inhibitors remains a major focus at #EULAR2026. In #OP086, analysis from 14 international RA registries and >60000 treatment courses found no statistically significant increase in overall or subtype-specific malignancy risk with JAKi versus TNFi. @RheumNow https://t.co/JeOmTufYwo
Antoni Chan MD (Prof)
Tweet
#EULAR2026 Abstr# OP06 9 TOGETHER-PsA: Adding tirzepatide to ixekizumab in #PsA + obesity achieved the primary composite (ACR50 + ≥10% weight loss) in 31.7% vs just 0.8% with IXE alone at 36 weeks (p<0.001). The first trial tackling PsA + obesity simultaneously @RheumNow https://t.co/0cDAj1y7OF
Antoni Chan MD (Prof)
Tweet
Abst# OP068: 68Ga-RGD PET/CT imaging detected subclinical synovitis in 35% of joints that were clinically silent in #PsA. Molecular imaging may reveal the true burden of joint disease before it declares clinically. @RheumNow #EULAR2026 #PsoriaticArthritis
Aurelie Najm
Tweet
Small interventional synovial biopsy precision medicine study
CD117 high pts n=15 = better response to IL17i or IL23i inhibition vs. TNFi w/
-DAPSA -13.5, -12.8 vs. -7.5 respectively
Higher BL levels of tissue inflammation in Responders vs. NR
More robust study design needed https://t.co/7jNff6lUJ6
Mrinalini Dey
Tweet
#OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment initiations, JAKis were associated with higher VTE risk vs TNFi (HR 1.89), with similar findings persisting in 2021-2024 data. @RheumNow https://t.co/YRjPNZ8mmo
Md Yuzaiful Md Yusof
Tweet
#EULAR2026 OP076 Of 50 patients treated with autologous CAR-T, 12% relapsed; median 13 mths. More frequent in #IIM vs #SLE or #SSc. These relapses were significant. Switching to BCMA-CAR or BCMA-TCE restored response. Should BCMA instead of CD19 be targeted initially?@RheumNow https://t.co/lgdsJQm3xY
Mrinalini Dey
Tweet
Kicking off Clinical Abstracts: Comorbidities in RA session at #EULAR2026 with #OP084
ANCHOR-RA found 9.1% at-risk RA patients had previous undiagnosed ILD on screening HRCT. Older age, smoking, male sex & ⬆️DAS28 linked to RA-ILD. Important data for earlier detection @RheumNow
Nelly ZIADE 🍀
Tweet
💊 Oral IL-23Ri for #PsA #PsO?
ICONIC RCT (n=216):
Yes! Icotrokinra improves pain & disease activity at week 16
#POS0052 #EULAR2026 @RheumNow https://t.co/PA4O36h02Y
Nelly ZIADE 🍀
Tweet
🛡️ Can secukinumab prevent #PsA?
SERENA real-world study (n=1,334):
Yes!
97% PsA-free at 5yrs
#POS0051 #EULAR2026 @rheumnow
Nelly ZIADE 🍀
Tweet
💉 Add tirzepatide to biologics in obese #PsA?
#POS0050: Yes! Propensity score-matched study (n=93):
better PROs, HAQ & PASI at 6 months
#EULAR2026 @RheumNow
@vincevenerito https://t.co/rrhNKZByjc
Nelly ZIADE 🍀
Tweet
🎯 Does Tofacitinib work in axial #PsA?
#POS0049: 1st RCT (PASTOR, n=26):
improved MRI & clinical outcomes vs placebo @ wk12
#EULAR2026 @rheumnow
